BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Nam, Soo Kyung ^a   Yun, Sumi ^a,b   Koh, Jiwon ^b   Kwak, Yoonjin ^a,b   Seo, AnNa ^c   Park, Kyoung Un ^a   Kim, Duck Woo ^a   Kang, Sung Bum ^a   Kim, Woo Ho ^b   Lee, Hye Seung ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University   (South Korea)

^c Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN P21;

ADULT; ADVANCED CANCER; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISTANT METASTASIS; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HER2 GENE; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; ONCOGENE; ONCOGENE K RAS; PI3CA GENE; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; COLORECTAL TUMOR; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MUTATION; PATHOLOGY; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84962338741     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151865     Document Type: Article

References (34)

1. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499. doi: 10.1038/nrc2645 PMID: 19536109
2. Martin V, Landi L, Molinari F, Fountzilas G, Geva R, et al. (2013) HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 108: 668-675. doi: 10.1038/bjc.2013.4 PMID: 23348520
3. Leto SM, Trusolino L (2014) Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. J Mol Med (Berl) 92: 709-722.
4. Er TK, Chen CC, Bujanda L, Herreros-Villanueva M (2014) Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patients. Biomed Res Int 2014: 591867. doi: 10. 1155/2014/591867 PMID: 25032217
5. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov 4: 1269-1280. doi: 10.1158/2159-8290.CD-14-0462 PMID: 25293556
6. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL (2012) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 23: 1518-1525. doi: 10.1093/annonc/mdr464 PMID: 22039088
7. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, et al. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486: 532-536. doi: 10. 1038/nature11156 PMID: 22722830
8. van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, et al. (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453: 417-431. doi: 10.1007/s00428-008-0665-y PMID: 18802721
9. Shaib W, Mahajan R, El-Rayes B (2013) Markers of resistance to anti-EGFR therapy in colorectal cancer. J Gastrointest Oncol 4: 308-318. doi: 10.3978/j.issn.2078-6891.2013.029 PMID: 23997942
10. Cantwell-Dorris ER, O'Leary JJ, Sheils OM (2011) BRAFV600E: implications for carcinogenesis and molecular therapy. Mol Cancer Ther 10: 385-394. doi: 10.1158/1535-7163.MCT-10-0799 PMID: 21388974
11. Yokota T (2012) Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer Agents Med Chem 12: 163-171. PMID: 22043994
12. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapyrefractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762. doi: 10.1016/S1470-2045(10)70130-3 PMID: 20619739
13. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, et al. (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3: 99ra86. doi: 10.1126/scitranslmed.3002442 PMID: 21900593
14. Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, et al. (2012) Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12: 347. doi: 10.1186/1471-2407-12-347 PMID: 22876814
15. Seo AN, Kwak Y, Kim DW, Kang SB, Choe G, et al. (2014) HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS One 9: e98528. doi: 10.1371/journal.pone.0098528 PMID: 24879338
16. Oh JR, Kim DW, Lee HS, Lee HE, Lee SM, et al. (2012) Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer 11: 459-466. doi: 10.1007/s10689-012-9536-4 PMID: 22669410
17. Kim JH, Bae JM, Kim KJ, Rhee YY, Kim Y, et al. (2014) Differential Features of Microsatellite-Unstable Colorectal Carcinomas Depending on EPCAM Expression Status. Korean J Pathol 48: 276-282. doi: 10.4132/KoreanJPathol.2014.48.4.276 PMID: 25214859
18. Kumler I, Tuxen MK, Nielsen DL (2014) A systematic review of dual targeting in HER2-positive breast cancer. Cancer Treat Rev 40: 259-270. doi: 10.1016/j.ctrv.2013.09.002 PMID: 24080156
19. Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, et al. (2014) HER2/neu testing in primary colorectal carcinoma. Br J Cancer 111: 1977-1984. doi: 10.1038/bjc.2014.483 PMID: 25211663
20. Neumann J, Wehweck L, Maatz S, Engel J, Kirchner T, et al. (2013) Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis. Virchows Arch 463: 509-523. doi: 10.1007/ s00428-013-1450-0 PMID: 23934607
21. Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, et al. (2015) A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer 15: 258. doi: 10.1186/s12885-015-1276-z PMID: 25886136
22. Zhang J, Roberts TM, Shivdasani RA (2011) Targeting PI3K signaling as a therapeutic approach for colorectal cancer. Gastroenterology 141: 50-61. doi: 10.1053/j.gastro.2011.05.010 PMID: 21723986
23. Temraz S, Mukherji D, Shamseddine A (2015) Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. Int J Mol Sci 16: 22976-22988. doi: 10.3390/ijms160922976 PMID: 26404261
24. Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083. doi: 10.1200/JCO.2009.25.3641 PMID: 20085938
25. Sahin IH, Kazmi SM, Yorio JT, Bhadkamkar NA, Kee BK, et al. (2013) Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature. J Cancer 4: 320-322. doi: 10.7150/jca.3619 PMID: 23569465
26. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29: 2011-2019. doi: 10.1200/JCO.2010.33.5091 PMID: 21502544
27. Oliveira C, Velho S, Moutinho C, Ferreira A, Preto A, et al. (2007) KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 26: 158-163. PMID: 16953233
28. Ma BB, Mo F, Tong JH, Wong A, Wong SC, et al. (2015) Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer. Asia Pac J Clin Oncol 11: 160-169. doi: 10.1111/ajco.12342 PMID: 25865669
29. Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, et al. (2014) Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer 13: 135. doi: 10.1186/1476-4598-13-135 PMID: 24885062
30. Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, et al. (2014) Clinical meaning of BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 20: 4370-4376. doi: 10.3748/wjg.v20. i15.4370 PMID: 24764675
31. Lee S, Brophy VH, Cao J, Velez M, Hoeppner C, et al. (2012) Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Virchows Arch 460: 141-149. doi: 10.1007/s00428-011-1180-0 PMID: 22173329
32. Arcila M, Lau C, Nafa K, Ladanyi M (2011) Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 13: 64-73. doi: 10.1016/j.jmoldx.2010.11.005 PMID: 21227396
33. Normanno N, Rachiglio AM, Lambiase M, Martinelli E, Fenizia F, et al. (2015) Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 26: 1710-1714. doi: 10.1093/annonc/mdv176 PMID: 25851630
34. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, et al. (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16: 790-799. doi: 10.1158/1078-0432.CCR-09-2446 PMID: 20103678